Supplementary Figure 4: m⁶A regulates NSC gene expression through histone modifications

(a) Numbers of gene counts and exact P values for each GO term displayed in Fig. 5b and 5c. (b) The association between m⁶A targets and differential gene expression in Mettl14 KO vs. nondeleted control NSCs determined by two-tailed Fisher’s Exact Test. A transcript is defined as an m⁶A target when a m⁶A peak is detected from either one of the two biological replicates in m⁶A meRIP-seq experiment. The numbers of genes in each category and exact P value are shown in the graph. (c) MTT cell growth assay of NSCs treated with vehicle/DMSO or the MLL1 inhibitor MM-102, the CBP/P300 inhibitor C646, or the Ezh2 inhibitor GSK343. Shown is the absorbance ratio of heterozygous to non-deleted controls at each dose. One-way ANOVA (n = 3 independent experiments for all experimental groups; GSK343, P = 0.1352, F (3, 8) = 2.482; C646, P = 0.0528, F (3, 8) = 3.971; MM-102, P = 0.5055, F (3, 8) = 0.8478) followed by Bonferroni's post hoc test (GSK343, c vs. 1.25, P = 0.9999, 95% C.I. = −0.2624 to 0.1392, c vs. 2.5, P = 0.0932, 95% C.I. = −0.3746 to 0.02694, c vs. 5, P = 0.3732, 95% C.I. = −0.3151 to 0.08651; C646, c vs. 1.25, P = 0.3132, 95% C.I. = −0.1995 to 0.04874, c vs. 2.5, P = 0.4435, 95% C.I. = −0.0582 to 0.1901, c vs. 5, P = 0.9999, 95% C.I. = −0.1164 to 0.1319; MM-102, c vs. 0.0625, P = 0.9999, 95% C.I. = −0.1997 to 0.3001, c vs. 1.25, P = 0.9999, 95% C.I. = −0.3251 to 0.1747, c vs. 2.5, P = 0.9999, 95% C.I. = −0.2263 to 0.2734). Graphs represent the mean ± SD. Dots represent data from individual data points.